deferoxamine has been researched along with Alloxan Diabetes in 43 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 7.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 5.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| " In the present study, we investigated the role of deferoxamine (DFO), as a clinical iron chelator, in improvement of type 1 diabetes-induced cognitive dysfunction." | 3.96 | Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction. ( Nahavandi, A; Zare, M; Zeinivand, M, 2020) |
| "Although the systemic administration of deferoxamine (DFO) is protective in experimental models of normal ischemic flap and diabetic wound, its effect on diabetic flap ischemia using a local injection remains unknown." | 3.80 | Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expression. ( Cai, Y; Cui, L; Li, G; Wang, C; Xiong, Z; Zhang, Y, 2014) |
| "The effect of superoxide dismutase, catalase, metal-chelating agents and hydroxyl radical scavengers on the toxicity of alloxan to isolated ob/ob mouse pancreatic islets in vitro has been compared with the reported ability of such substances to protect against alloxan diabetes in vivo." | 3.70 | Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro. ( Jörns, A; Lenzen, S; Munday, R; Tiedge, M, 1999) |
| "Alloxan diabetes may be mediated by an iron-catalyzed formation of hydroxyl radicals." | 3.66 | Opposite effects of two metal-chelators on alloxan-induced diabetes in mice. ( Grankvist, K; Marklund, SL, 1983) |
| "After 8 weeks of type 2 diabetes induced by a combination of high-fat diet and low-dose streptozotocin, male control and diabetic animals were subjected to thromboembolic middle cerebral artery occlusion (MCAO) and randomized to vehicle, DFX, or tPA/DFX and followed for 14 days with behavioral tests." | 1.62 | Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. ( Abdelsaid, M; Abdul, Y; Dong, G; Ergul, A; Fagan, SC; Hafez, S; Jamil, S; Johnson, MH; Li, W; Ward, R; Wolf, V, 2021) |
| "Deferoxamine has shown cutaneous wound healing potential by increased neovascularization." | 1.42 | Deferoxamine modulates cytokines and growth factors to accelerate cutaneous wound healing in diabetic rats. ( Kumar Tandan, S; Kumar, D; Kumawat, S; Lingaraju, MC; Rahal, A; Ram, M; Singh, V; Uttam Singh, T, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.98) | 18.7374 |
| 1990's | 7 (16.28) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 19 (44.19) | 24.3611 |
| 2020's | 7 (16.28) | 2.80 |
| Authors | Studies |
|---|---|
| Aneesha, VA | 2 |
| Qayoom, A | 2 |
| Anagha, S | 2 |
| Almas, SA | 1 |
| Naresh, VK | 1 |
| Kumawat, S | 2 |
| Singh, WR | 1 |
| Sadam, A | 1 |
| Dinesh, M | 1 |
| Shyamkumar, TS | 1 |
| Sahoo, M | 1 |
| Lingaraju, MC | 2 |
| Singh, TU | 1 |
| Kumar, D | 4 |
| Li, N | 1 |
| Zhan, A | 1 |
| Jiang, Y | 1 |
| Liu, H | 1 |
| Li, W | 2 |
| Abdul, Y | 2 |
| Chandran, R | 1 |
| Jamil, S | 2 |
| Ward, RA | 1 |
| Abdelsaid, M | 2 |
| Dong, G | 2 |
| Fagan, SC | 2 |
| Ergul, A | 2 |
| Sakamuri, SSVP | 1 |
| Sure, VN | 1 |
| Katakam, PVG | 1 |
| Zeinivand, M | 1 |
| Nahavandi, A | 1 |
| Zare, M | 1 |
| Hopfner, U | 1 |
| Maan, ZN | 2 |
| Hu, MS | 1 |
| Aitzetmüller, MM | 1 |
| Zaussinger, M | 1 |
| Kirsch, M | 1 |
| Machens, HG | 1 |
| Duscher, D | 2 |
| Ward, R | 1 |
| Hafez, S | 1 |
| Wolf, V | 1 |
| Johnson, MH | 1 |
| Xie, P | 1 |
| Yang, L | 1 |
| Talaiti, A | 1 |
| Wu, JJ | 1 |
| Yu, J | 1 |
| Yu, T | 1 |
| Wang, HY | 1 |
| Huang, B | 1 |
| Wu, Q | 1 |
| Maimaitili, Y | 1 |
| Wang, J | 1 |
| Ma, HP | 1 |
| Yang, YN | 1 |
| Zheng, H | 1 |
| Bellanti, F | 1 |
| Gao, SQ | 1 |
| Chang, C | 1 |
| Li, JJ | 1 |
| Li, Y | 1 |
| Niu, XQ | 1 |
| Zhang, DP | 1 |
| Li, LJ | 1 |
| Gao, JQ | 1 |
| Yuan, C | 1 |
| Wang, H | 1 |
| Yuan, Z | 1 |
| Dar, JA | 1 |
| Kumar, P | 1 |
| Najafi, R | 1 |
| Sharifi, AM | 2 |
| Egan, CG | 1 |
| Hou, Z | 1 |
| Nie, C | 1 |
| Si, Z | 1 |
| Ma, Y | 1 |
| Wang, C | 1 |
| Cai, Y | 1 |
| Zhang, Y | 1 |
| Xiong, Z | 1 |
| Li, G | 1 |
| Cui, L | 1 |
| Scott, C | 1 |
| Bonner, J | 1 |
| Min, D | 1 |
| Boughton, P | 1 |
| Stokes, R | 1 |
| Cha, KM | 1 |
| Walters, SN | 1 |
| Maslowski, K | 1 |
| Sierro, F | 1 |
| Grey, ST | 1 |
| Twigg, S | 1 |
| McLennan, S | 1 |
| Gunton, JE | 1 |
| Kuchler, U | 1 |
| Keibl, C | 1 |
| Fügl, A | 1 |
| Schwarze, UY | 1 |
| Tangl, S | 1 |
| Agis, H | 1 |
| Gruber, R | 1 |
| Neofytou, E | 1 |
| Wong, VW | 1 |
| Rennert, RC | 1 |
| Inayathullah, M | 1 |
| Januszyk, M | 2 |
| Rodrigues, M | 1 |
| Malkovskiy, AV | 1 |
| Whitmore, AJ | 1 |
| Walmsley, GG | 1 |
| Galvez, MG | 2 |
| Whittam, AJ | 1 |
| Brownlee, M | 2 |
| Rajadas, J | 1 |
| Gurtner, GC | 2 |
| Ram, M | 1 |
| Singh, V | 1 |
| Uttam Singh, T | 1 |
| Rahal, A | 1 |
| Kumar Tandan, S | 1 |
| Mehrabani, M | 1 |
| Najafi, M | 1 |
| Kamarul, T | 1 |
| Mansouri, K | 1 |
| Iranpour, M | 1 |
| Nematollahi, MH | 1 |
| Ghazi-Khansari, M | 1 |
| Réus, GZ | 2 |
| Dos Santos, MA | 1 |
| Abelaira, HM | 2 |
| Titus, SE | 1 |
| Carlessi, AS | 1 |
| Matias, BI | 2 |
| Bruchchen, L | 2 |
| Florentino, D | 1 |
| Vieira, A | 1 |
| Petronilho, F | 1 |
| Ceretta, LB | 1 |
| Zugno, AI | 2 |
| Quevedo, J | 2 |
| Chen, H | 1 |
| Jia, P | 1 |
| Kang, H | 1 |
| Zhang, H | 1 |
| Liu, Y | 2 |
| Yang, P | 1 |
| Yan, Y | 1 |
| Zuo, G | 1 |
| Guo, L | 1 |
| Jiang, M | 1 |
| Qi, J | 1 |
| Cui, W | 1 |
| Santos, HA | 1 |
| Deng, L | 1 |
| Bernardini Dos Santos, MA | 1 |
| Maciel, AL | 1 |
| Arent, CO | 1 |
| Ignácio, ZM | 1 |
| Michels, M | 1 |
| Dal-Pizzol, F | 1 |
| Carvalho, AF | 1 |
| Thangarajah, H | 1 |
| Yao, D | 1 |
| Chang, EI | 1 |
| Shi, Y | 1 |
| Jazayeri, L | 1 |
| Vial, IN | 1 |
| Galiano, RD | 1 |
| Du, XL | 1 |
| Grogan, R | 1 |
| Vaithilingam, V | 1 |
| Oberholzer, J | 1 |
| Guillemin, GJ | 1 |
| Tuch, BE | 1 |
| Francés, DE | 1 |
| Ronco, MT | 1 |
| Ingaramo, PI | 1 |
| Monti, JA | 1 |
| Pisani, GB | 1 |
| Parody, JP | 1 |
| Pellegrino, JM | 1 |
| Carrillo, MC | 1 |
| Martín-Sanz, P | 1 |
| Carnovale, CE | 1 |
| Iino, K | 1 |
| Iwase, M | 1 |
| Sonoki, K | 1 |
| Yoshinari, M | 1 |
| Iida, M | 1 |
| Asleh, R | 1 |
| Guetta, J | 1 |
| Kalet-Litman, S | 1 |
| Miller-Lotan, R | 1 |
| Levy, AP | 1 |
| Grankvist, K | 1 |
| Marklund, SL | 1 |
| Cameron, NE | 2 |
| Cotter, MA | 2 |
| Ress, AM | 1 |
| Babovic, S | 1 |
| Angel, MF | 1 |
| Im, MJ | 1 |
| Dellon, AL | 1 |
| Manson, PN | 1 |
| Young, IS | 1 |
| Tate, S | 1 |
| Lightbody, JH | 1 |
| McMaster, D | 1 |
| Trimble, ER | 1 |
| Pieper, GM | 1 |
| Siebeneich, W | 1 |
| Whiting, PH | 1 |
| Jiffri, E | 1 |
| Thomson, L | 1 |
| Beaton, W | 1 |
| Williamson, FW | 1 |
| Long, WF | 1 |
| Jörns, A | 1 |
| Tiedge, M | 1 |
| Lenzen, S | 1 |
| Munday, R | 1 |
| Hattori, Y | 1 |
| Matsuda, N | 1 |
| Sato, A | 1 |
| Watanuki, S | 1 |
| Tomioka, H | 1 |
| Kawasaki, H | 1 |
| Kanno, M | 1 |
| Karasu, C | 1 |
| Chen, HC | 1 |
| Guh, JY | 1 |
| Shin, SJ | 1 |
| Tsai, JH | 1 |
| Lai, YH | 1 |
| Anand, VK | 1 |
| Alemar, G | 1 |
| Griswold, JA | 1 |
| Mendola, J | 1 |
| Wright, JR | 1 |
| Lacy, PE | 1 |
| Hermitte, L | 1 |
| Vialettes, B | 1 |
| Atlef, N | 1 |
| Payan, MJ | 1 |
| Doll, N | 1 |
| Scheimann, A | 1 |
| Vague, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients[NCT02771808] | 83 participants (Actual) | Observational | 2010-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Alloxan Diabetes
| Article | Year |
|---|---|
Intracranial complications of mucormycosis: an experimental model and clinical review.
Topics: Adult; Alloxan; Amphotericin B; Animals; Brain Abscess; Brain Diseases; Child; Deferoxamine; Diabete | 1992 |
42 other studies available for deferoxamine and Alloxan Diabetes
| Article | Year |
|---|---|
Topical bilirubin-deferoxamine hastens excisional wound healing by modulating inflammation, oxidative stress, angiogenesis, and collagen deposition in diabetic rats.
Topics: Animals; Antioxidants; Bilirubin; Collagen; Deferoxamine; Diabetes Mellitus, Experimental; Inflammat | 2022 |
A novel matrix metalloproteinases-cleavable hydrogel loading deferoxamine accelerates diabetic wound healing.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetic Foot; Hydrogels; Matrix Metalloprot | 2022 |
Deferoxamine prevents poststroke memory impairment in female diabetic rats: potential links to hemorrhagic transformation and ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Female; Ferroptosis; Hemin; Male; Rats; Stro | 2023 |
Iron chelation therapy to prevent poststroke cognitive impairments: role of diabetes and sex.
Topics: Animals; Chelation Therapy; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, Experimental; Fe | 2023 |
Deferoxamine regulates neuroinflammation and oxidative stress in rats with diabetes-induced cognitive dysfunction.
Topics: Animals; Avoidance Learning; Brain Diseases; Cognitive Dysfunction; Deferoxamine; Diabetes Mellitus, | 2020 |
Deferoxamine enhances the regenerative potential of diabetic Adipose Derived Stem Cells.
Topics: Adult; Aged; Animals; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Experimental; Humans; Hypoxi | 2020 |
Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelial Cells | 2021 |
Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats.
Topics: Anesthetics, Inhalation; Animals; Deferoxamine; Diabetes Mellitus, Experimental; Gene Expression Reg | 2017 |
Hypoxia-inducible factor-1 in myocardial ischaemia/reperfusion injury.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Hypoxia; Hypoxia-Inducible Factor 1; Rats; S | 2017 |
Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis.
Topics: Administration, Topical; Animals; Chalcone; Deferoxamine; Diabetes Mellitus, Experimental; Drug Deli | 2018 |
Ginsenoside Rg1 inhibits myocardial ischaemia and reperfusion injury
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Deferoxamine; Diabetes Mellitus, Experimental; Extracellul | 2019 |
Lecithin-based deferoxamine nanoparticles accelerated cutaneous wound healing in diabetic rats.
Topics: Animals; Chemokine CXCL12; Collagen; Deferoxamine; Diabetes Mellitus, Experimental; Drug Carriers; G | 2019 |
Deferoxamine preconditioning potentiates mesenchymal stem cell homing in vitro and in streptozotocin-diabetic rats.
Topics: Animals; Apoptosis; Blotting, Western; Cell Adhesion; Cell Differentiation; Cell Movement; Cell Prol | 2013 |
Potential therapeutic use of deferoxamine and mesenchymal stem cells in type-1 diabetes: assembling another piece of the jigsaw, in what is a complex puzzle.
Topics: Animals; Cell Movement; Cell Proliferation; Deferoxamine; Diabetes Mellitus, Experimental; Male; Mes | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Deferoxamine enhances neovascularization and accelerates wound healing in diabetic rats via the accumulation of hypoxia-inducible factor-1α.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Deferoxamine; Diabetes Mellitus, Ex | 2013 |
Local injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expression.
Topics: Animals; Cell Movement; Cell Survival; Deferoxamine; Diabetes Mellitus, Experimental; Dose-Response | 2014 |
Reduction of ARNT in myeloid cells causes immune suppression and delayed wound healing.
Topics: Aged; Animals; Aryl Hydrocarbon Receptor Nuclear Translocator; Case-Control Studies; Cells, Cultured | 2014 |
Dimethyloxalylglycine lyophilized onto bone substitutes increase vessel area in rat calvarial defects.
Topics: Angiogenesis Inducing Agents; Animals; Bone Regeneration; Bone Substitutes; Deferoxamine; Diabetes M | 2015 |
Transdermal deferoxamine prevents pressure-induced diabetic ulcers.
Topics: Administration, Cutaneous; Animals; Apoptosis; Deferoxamine; Dermis; Diabetes Complications; Diabete | 2015 |
Deferoxamine modulates cytokines and growth factors to accelerate cutaneous wound healing in diabetic rats.
Topics: Animals; Cytokines; Deferoxamine; Diabetes Mellitus, Experimental; Gene Expression Regulation; Inter | 2015 |
Deferoxamine preconditioning to restore impaired HIF-1α-mediated angiogenic mechanisms in adipose-derived stem cells from STZ-induced type 1 diabetic rats.
Topics: Adipose Tissue; Animals; Cell Movement; Cell Survival; Cells, Cultured; Chemokine CXCL12; Deferoxami | 2015 |
Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behaviour and reduces oxidative stress in brain and pancreas.
Topics: Acetylcysteine; Animals; Antioxidants; Behavior, Animal; Brain; Deferoxamine; Depressive Disorder; D | 2016 |
Upregulating Hif-1α by Hydrogel Nanofibrous Scaffolds for Rapidly Recruiting Angiogenesis Relative Cells in Diabetic Wound.
Topics: Animals; Biocompatible Materials; Chitosan; Deferoxamine; Dermis; Diabetes Mellitus, Experimental; D | 2016 |
Antioxidant Therapy Alters Brain MAPK-JNK and BDNF Signaling Path-ways in Experimental Diabetes Mellitus.
Topics: Acetylcysteine; Analysis of Variance; Animals; Antioxidants; Brain; Brain-Derived Neurotrophic Facto | 2016 |
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.
Topics: Animals; Cells, Cultured; Deferoxamine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus | 2009 |
Beneficial effects of desferrioxamine on encapsulated human islets--in vitro and in vivo study.
Topics: Animals; Apoptosis; Blood Glucose; Cadaver; Caspases; Cell Line; Cell Survival; Deferoxamine; Diabet | 2010 |
Role of reactive oxygen species in the early stages of liver regeneration in streptozotocin-induced diabetic rats.
Topics: Animals; Cyclic N-Oxides; Deferoxamine; Diabetes Mellitus, Experimental; Disease Models, Animal; Hep | 2011 |
Combination treatment of vitamin C and desferrioxamine suppresses glomerular superoxide and prostaglandin E production in diabetic rats.
Topics: Animals; Ascorbic Acid; Deferoxamine; Depression, Chemical; Diabetes Mellitus, Experimental; Dinopro | 2005 |
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo.
Topics: Alleles; Animals; CHO Cells; Cricetinae; Cricetulus; Deferoxamine; Diabetes Mellitus, Experimental; | 2005 |
Opposite effects of two metal-chelators on alloxan-induced diabetes in mice.
Topics: Alloxan; Animals; Blood Glucose; Deferoxamine; Diabetes Mellitus, Experimental; Hydrogen Peroxide; M | 1983 |
Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents.
Topics: Animals; Cell Hypoxia; Chelating Agents; Chelation Therapy; Deferoxamine; Diabetes Mellitus, Experim | 1995 |
Free radical damage in acute nerve compression.
Topics: Animals; Antioxidants; Deferoxamine; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Female; | 1995 |
The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat.
Topics: Animals; Ascorbic Acid; Blood Glucose; Cholesterol; Copper; Deferoxamine; Diabetes Mellitus, Experim | 1995 |
Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine.
Topics: Animals; Blood Glucose; Deferoxamine; Diabetes Mellitus, Experimental; Dose-Response Relationship, D | 1997 |
The effect of desferrioxamine on the development of renal dysfunction in streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Creatinine; Deferoxamine; Diabetes Mellitus, Experimental; Diabetic Nephropa | 1997 |
Effect of superoxide dismutase, catalase, chelating agents, and free radical scavengers on the toxicity of alloxan to isolated pancreatic islets in vitro.
Topics: 1-Butanol; Alloxan; Animals; Antioxidants; Catalase; Chelating Agents; Deferoxamine; Diabetes Mellit | 1999 |
Predominant contribution of the G protein-mediated mechanism to NaF-induced vascular contractions in diabetic rats: association with an increased level of G(qalpha) expression.
Topics: Aluminum Chloride; Aluminum Compounds; Animals; Aorta, Thoracic; Astringents; Blotting, Western; Che | 2000 |
Time course of changes in endothelium-dependent and -independent relaxation of chronically diabetic aorta: role of reactive oxygen species.
Topics: Acetylcholine; Amitrole; Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Catalase; Chronic Dis | 2000 |
Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo.
Topics: Animals; Catalase; Deferoxamine; Diabetes Mellitus, Experimental; Dimethyl Sulfoxide; Endothelin-1; | 2000 |
Effects of an extracellular metal chelator on neurovascular function in diabetic rats.
Topics: Animals; Blood Glucose; Deferoxamine; Diabetes Mellitus, Experimental; Hydroxyethyl Starch Derivativ | 2001 |
Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis.
Topics: Animals; Deferoxamine; Diabetes Mellitus, Experimental; Free Radicals; Graft Rejection; Islets of La | 1989 |
High dose nicotinamide fails to prevent diabetes in BB rats.
Topics: Age Factors; Animals; Autoimmune Diseases; Blood Glucose; Cyclosporine; Deferoxamine; Diabetes Melli | 1989 |